R Squared Ltd Invests $209,000 in Ascendis Pharma A/S $ASND

R Squared Ltd purchased a new position in shares of Ascendis Pharma A/S (NASDAQ:ASND) during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 1,212 shares of the biotechnology company’s stock, valued at approximately $209,000.

A number of other hedge funds and other institutional investors have also made changes to their positions in the stock. Vident Advisory LLC bought a new stake in Ascendis Pharma A/S in the 1st quarter valued at $273,000. Goldman Sachs Group Inc. lifted its position in Ascendis Pharma A/S by 10.4% in the 1st quarter. Goldman Sachs Group Inc. now owns 585,581 shares of the biotechnology company’s stock valued at $91,269,000 after acquiring an additional 55,164 shares in the last quarter. Adage Capital Partners GP L.L.C. bought a new stake in Ascendis Pharma A/S in the 1st quarter valued at $51,029,000. HighTower Advisors LLC lifted its position in Ascendis Pharma A/S by 413.1% in the 1st quarter. HighTower Advisors LLC now owns 18,032 shares of the biotechnology company’s stock valued at $2,810,000 after acquiring an additional 14,518 shares in the last quarter. Finally, Cinctive Capital Management LP bought a new stake in Ascendis Pharma A/S in the 1st quarter valued at $1,191,000.

Ascendis Pharma A/S Trading Up 0.5%

Shares of ASND stock opened at $202.00 on Friday. Ascendis Pharma A/S has a 1 year low of $118.03 and a 1 year high of $216.45. The firm’s fifty day moving average price is $199.92 and its two-hundred day moving average price is $179.75. The firm has a market capitalization of $12.46 billion, a P/E ratio of -39.15 and a beta of 0.41.

Ascendis Pharma A/S (NASDAQ:ASND) last released its quarterly earnings data on Thursday, August 7th. The biotechnology company reported ($0.93) earnings per share for the quarter, topping the consensus estimate of ($1.42) by $0.49. The firm had revenue of $216.28 million for the quarter, compared to analyst estimates of $163.17 million. As a group, equities research analysts forecast that Ascendis Pharma A/S will post -4.34 EPS for the current fiscal year.

Analysts Set New Price Targets

Several research firms recently commented on ASND. Royal Bank Of Canada boosted their price objective on shares of Ascendis Pharma A/S from $210.00 to $230.00 and gave the company an “outperform” rating in a research report on Friday, August 8th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Ascendis Pharma A/S in a research report on Friday. Raymond James Financial started coverage on shares of Ascendis Pharma A/S in a research report on Friday, October 17th. They issued a “strong-buy” rating and a $271.00 price objective on the stock. Cantor Fitzgerald lifted their price target on shares of Ascendis Pharma A/S from $203.00 to $254.00 and gave the company an “overweight” rating in a research note on Monday, October 13th. Finally, Morgan Stanley started coverage on shares of Ascendis Pharma A/S in a research note on Thursday, July 3rd. They issued an “overweight” rating and a $250.00 price target on the stock. One research analyst has rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $249.80.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.